Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
45 hedge funds and large institutions have $62.3M invested in Sinovac Biotech, Ltd in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 7 closing their positions.
10% less funds holding
Funds holding: 50 → 45 (-5)
16% less capital invested
Capital invested by funds: $74.3M → $62.3M (-$12.1M)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
57% less call options, than puts
Call options by funds: $65K | Put options by funds: $150K
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.36M |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$4.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.68M |
| 4 |
Morgan Stanley
New York
|
+$509K |
| 5 |
Renaissance Technologies
New York
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$7.05M |
| 2 |
VAM
Visium Asset Management
New York
|
-$5.64M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.84M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$771K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$259K |
SVA Hedge Fund Activity: Q3 2014 in Review
45 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2014, worth a combined $62.3M — down 16% from $74.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SVA and 2 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was OrbiMed, adding an estimated $6.36M. The largest seller was Davis Selected Advisers, exiting entirely with an estimated $7.05M sold.
- 45 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2014, down from 50 in Q2 2014.
- Funds reported $62.3M of Sinovac Biotech, Ltd stock for Q3 2014, down 16% quarter-over-quarter.
- 2 funds opened new Sinovac Biotech, Ltd positions in Q3 2014 and 7 closed out, a net change of -5 holders.
- The largest Sinovac Biotech, Ltd buyer in Q3 2014 was OrbiMed, an estimated $6.36M added.
- The largest Sinovac Biotech, Ltd seller in Q3 2014 was Davis Selected Advisers, an estimated $7.05M sold.
Based on aggregated 13F filings for Q3 2014.